CompletedPhase 4

Safety and Immunogenicity of Concomitant Administration of EV71 Vaccine With Expanded Programme on Immunization Vaccines

China372 participantsStarted 2019-07-26

Plain-language summary

The purpose of this study is to evaluate the safety and immunogenicity of concomitant administration of EV71 vaccine with measles mumps, and rubella combined live attenuated vaccine/ encephalitis live attenuated vaccine.

Who can participate

Age range8 Months

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. Blood product within 3 months prior to study entry;
✕. Any live attenuated vaccine within 14 days prior to study entry;
✕. Any subunit vaccine or inactivated vaccine within 7 days prior to study entry;
✕. Any other study drugs within 30 days prior to study entry;

What they're measuring

The seroconversion rates（SCR） of the EV71 neutralizing antibody 30 days after two dose of EV71 vaccines

Timeframe: 30 days after two dose of EV71 vaccines

Trial details

NCT IDNCT04111432

SponsorSinovac Biotech Co., Ltd

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2019-11-25

View on ClinicalTrials.gov More Hand, Foot and Mouth Disease trials